Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy

Molecular Cancer Therapeutics

Volumn 3, Issue 5, 2004, Pages 633-639

  Gouazé, Valerie ^a   Yu, Jing Y ^a   Bleicher, Richard J ^d   Han, Tie Yan ^a   Liu, Yong Yu ^a   Wang, Hongtao ^a   Gottesman, Michael M ^b   Bitterman, Arie ^c   Giuliano, Armando E ^a   Cabot, Myles C ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Carmel Medical center ^*  (Israel)

^d PALO ALTO MEDICAL FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; CERAMIDE GLUCOSYLTRANSFERASE; DOXORUBICIN; ETOPOSIDE; GLUCOSYLCERAMIDE; GLYCOPROTEIN P; MESSENGER RNA; VINBLASTINE; VINCA ALKALOID;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CATALYSIS; CELL LYSATE; CELL STRAIN KB; CELL STRAIN MCF 7; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GLYCOSYLATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LIPID METABOLISM; MELANOMA CELL; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SQUAMOUS CELL CARCINOMA; WILD TYPE;

BIOLOGICAL FACTORS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GLUCOSYLCERAMIDES; GLUCOSYLTRANSFERASES; HUMANS; P-GLYCOPROTEIN; RNA, MESSENGER; VINBLASTINE;

EID: 4444364174     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-27.
2. Bradley G, Ling VP. P-glycoprotein, multidrug resistance and tumor progression. Cancer Metast Rev 1994;13:223-33.
3. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2001;2:48-58.
4. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Orekovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 1997;(40 Suppl):S13-9.
5. Sandor V, Fojo T, Bates SE. Future perspective for the development of P-glycoprotein modulators. Drug Resistance Updates 1998;1:190-200.
6. Krishnamachary N, Center MS. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res 1993;53:3658-61.
7. Grant CE, Valdimarsson G, Hipfner Dr, Almquist KC, Cole SP, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994;54:357-61.
8. Deffie AM, Batra JK, Goldenberg GJ. Direct correlation between DNA topoisomerase II activity and cytotoxicity in Adriamycin-sensitive and resistant P388 leukemia cell lines. Cancer Res 1989;49:58-62.
9. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 1989;28:8154-60.
10. Zhang K, Mack P, Wong KP. Glutathione-related mechanisms in cellular resistance to anticancer drugs. Int J Oncol 1998;4:871-82.
11. Morrow CS, Cowan KH. Glutathione S-transferases and drug resistance. Cancer Cells 1990;2:15-22.
12. Reed JC. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 1995;5:541-6.
13. Mueller H, Eppenberger U. The dual role of mutant p53 protein in chemosensitivity in human cancers. Anticancer Res 1996;16:3845-8.
14. Kickhoefer VA, Rajavel KS, Schaffer GI, Dalton WS, Schaper RJ, Rome LH. Vaults are up-regulated in multidrug-resistant cancer cell lines. J Biol Chem 1998;273:8971-4.
15. Lavie Y, Fiucci G, Liscovitch M. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem 1998;273:32380-3.
16. Lutzker SG, Levine AJ. Apoptosis and cancer chemotherapy. Cancer Treat Res 1996;87:345-56.
17. Hannun YA, Obeid LM. Mechanisms of ceramide-mediated apoptosis. Adv Exp Med Biol 1997;407:145-9.
18. Lavie Y, Cao HT, Bursten SL, Giuliano AE, Cabot MC. Accumulation of glucosylceramide in multidrug resistant cancer cells. J Biol Chem 1996;271:19530-6.
19. Senchenkov A, Litvak DA, Cabot MC. Targeting ceramide metabolism - a strategy for overcoming drug resistance. J Natl Cancer Inst 2001;93:347-57.
20. Liu YY, Han TY, Giuliano AE, Cabot MC. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 2001;15:719-30.
21. Shen DW, Cardarelli C, Hwang J, et al. Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, Adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem 1986;261:7762-70.
22. Kern MA, Helmbach H, Artuc M, Karmann D, Jurgovsky K, Schadendorf D. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression. Anticancer Res 1997;17:4359-70.
23. Helmbach H, Kern MA, Rossmann E, et al. Drug resistance towards etoposide and cisplatin in human melanoma cells is associated with drug-dependent apoptosis deficiency. J Invest Dermatol 2002;118:923-32.
24. Lai GM, Chian YN, Mickley LA, Fojo AT, Bates SE. P-glycoprotein expression and schedule dependence of Adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 1991;49:696-703.
25. Shukla GS, Radin NS. Glucosylceramide synthase of mouse kidney: further characterization with an improved assay method. J Arch Biochem Biophys 1990;283:372-8.
26. Obeid LM, Linardic CM, Karolak LA, Hannun YA. Programmed cell death induced by ceramide. Science 1993;259:1769-71.
27. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 1995;82:405-14.
28. Liu Y-Y, Han T-Y, Giuliano AE, Cabot MC. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers Adriamycin resistance in human breast cancer cells. J Biol Chem 1999; 274:1140-6.
29. Liu YY, Han TY, Giuliano AE, Hansen N, Cabot MC. Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses Adriamycin resistance. J Biol Chem 2000;275: 7138-43.
30. Deng W, Li R, Guerrera M, Liu Y, Ladisch S. Transfection of glucosylceramide synthase antisense inhibits mouse melanoma formation. Glycobiology 2002;12:145-52.
31. Maurer BJ, Melton L, Billups C, Cabot MC, Reynolds CP. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl) retinamide and modulators of ceramide metabolism. J Natl Cancer Inst 2000;92:1897-909.
32. Sietsma H, Veldman RJ, Kolk D, et al. 1-phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine. Clin Cancer Res 2000;6:942-8.
33. O'Donnell PH, Guo WX, Reynolds CP, Maurer BJ. N-(4-hydroxyphenyl) retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes. Leukemia 2002;16:902-10.
34. Litvak DA, Bilchik AJ, Cabot MC. Modulators of ceramide metabolism sensitize colorectal cancer cells to chemotherapy. A novel treatment strategy. J Gastrointest Surg 2003;7:140-8.
35. Wang H, Charles AG, Frankel AJ, Cabot MC. Increasing intracellular ceramide: an approach that enhances the cytotoxic response in prostate cancer cells. Urology 2003;61:1047-52.
36. Lavie Y, Cao H, Volner A, et al. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin a, block glycosphingo-lipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 1997;272:1682-7.
37. Morjani H, Aouali N, Belhoussine R, Veldman RJ, Levade T, Manfait M. Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets. Int J Cancer 2001;94:157-65.
38. van Helvoort A, Smith AJ, Sprong H, et al. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 1996;87:507-17.
39. 6-NBD-sphingomyelin is translocated across the plasma membrane by a multidrug transporter activity. J Cell Sci 1997;110: 75-83.
40. Shabbits JA, Mayer LD. P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. Mol Cancer Ther 2002;1:205-13.
41. Plo I, Lehne G, Beckstrøm KJ, et al. Influence of ceramide metabolism on P-glycoprotein function in immature acute myeloid leukemia KG1a cells. Mol Pharmacol 2002;62:304-12.
42. Veldman RJ, Klappe K, Hinrichs J, et al. Altered sphingolipid metabolism in multidrug-resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus. FASEB J 2002;16: 1111-3.
43. Lucci A, Cho WI, Han TY, Giuliano AE, Morton DL, Cabot MC. Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Res 1998;18:475-80.
44. Goulding CW, Giuliano AE, Cabot MC. SDZ PSC 833 the drug resistance modulator activates cellular ceramide formation by a pathway independent of P-glycoprotein. Cancer Lett 2000;149:143-51.
45. Liu Y-Y, Yu J-Y, Gouazd V, et al. Doxorubicin drives drug resistance in breast cancer cells through ceramide-upregulated gene expression. Proc Am Assoc Cancer Res 2003;44:7-77.